DNA damage response to the Mdm2 inhibitor Nutlin-3

Biochemical Pharmacology

Volumn 79, Issue 4, 2010, Pages 565-574

  Verma, Rajeev ^a   Rigatti, Marc J ^a   Belinsky, Glenn S ^b   Godman, Cassandra A ^a   Giardina, Charles ^a  

^a UNIVERSITY OF CONNECTICUT   (United States)

^b UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

H2AX; Double strand DNA breaks; Doxorubicin; Mdm2 inhibitors; Nutlin 3; p53

Indexed keywords

AZOXYMETHANE; CLASTOGEN; DOXORUBICIN; FLUOROURACIL; GYRASE INHIBITOR; HISTONE H2AX; HYDROXYUREA; NUTLIN 3; PROTEIN MDM2; PROTEIN P21; PROTEIN P53; SERINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE S PHASE; CELL STRAIN HCT116; COLON CANCER; CONTROLLED STUDY; DNA DAMAGE; DNA REPAIR; DOUBLE STRANDED DNA BREAK; DRUG MECHANISM; DRUG SENSITIZATION; ENANTIOMER; GENE DELETION; HOMOLOGOUS RECOMBINATION; MICRONUCLEUS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; QUANTITATIVE ANALYSIS;

ANIMALS; DNA DAMAGE; HCT116 CELLS; HUMANS; IMIDAZOLES; MICE; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-MDM2; STEREOISOMERISM; TUMOR CELLS, CULTURED;

EID: 71549128983     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2009.09.020     Document Type: Article

References (59)

1. Shieh S.Y., Ikeda M., Taya Y., and Prives C. DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2. Cell 91 (October 31) 3 (1997) 325-334
2. Bean L.J., and Stark G.R. Regulation of the accumulation and function of p53 by phosphorylation of two residues within the domain that binds to Mdm2. J Biol Chem 277 (January 18) 3 (2002) 1864-1871
3. Araki R., Fukumura R., Fujimori A., Taya Y., Shiloh Y., Kurimasa A., et al. Enhanced phosphorylation of p53 serine 18 following DNA damage in DNA-dependent protein kinase catalytic subunit-deficient cells. Cancer Res 59 (August 1) 15 (1999) 3543-3546
4. Lowe S.W., Jacks T., Housman D.E., and Ruley H.E. Abrogation of oncogene-associated apoptosis allows transformation of p53-deficient cells. Proc Natl Acad Sci USA 91 (March 15) 6 (1994) 2026-2030
5. Honda R., and Yasuda H. Association of p19(ARF) with Mdm2 inhibits ubiquitin ligase activity of Mdm2 for tumor suppressor p53. EMBO J 18 January 4 (6) (1999) 22-27
6. Kamijo T., van de Kamp E., Chong M.J., Zindy F., Diehl J.A., Sherr C.J., et al. Loss of the ARF tumor suppressor reverses premature replicative arrest but not radiation hypersensitivity arising from disabled atm function. Cancer Res 59 May 15 (10) (1999) 2464-2469
7. Lohrum M.A., Ashcroft M., Kubbutat M.H., and Vousden K.H. Contribution of two independent MDM2-binding domains in p14(ARF) to p53 stabilization. Curr Biol 10 May 4 (9) (2000) 539-542
8. Stott F.J., Bates S., James M.C., McConnell B.B., Starborg M., Brookes S., et al. The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2. EMBO J 17 September 1 (17) (1998) 5001-5014
9. Tao W., and Levine A.J. P19(ARF) stabilizes p53 by blocking nucleo-cytoplasmic shuttling of Mdm2. Proc Natl Acad Sci USA 96 June 8 (12) (1999) 6937-6941
10. Tsantoulis P.K., Kotsinas A., Sfikakis P.P., Evangelou K., Sideridou M., Levy B., et al. Oncogene-induced replication stress preferentially targets common fragile sites in preneoplastic lesions. A genome-wide study. Oncogene 27 May 22 (23) (2008) 3256-3264
11. Bartek J., Bartkova J., and Lukas J. DNA damage signalling guards against activated oncogenes and tumour progression. Oncogene 26 December 10 (56) (2007) 7773-7779
12. Bartek J., Lukas J., and Bartkova J. DNA damage response as an anti-cancer barrier: damage threshold and the concept of 'conditional haploinsufficiency'. Cell Cycle 6 October 1 (19) (2007) 2344-2347
13. Mallette F.A., and Ferbeyre G. The DNA damage signaling pathway connects oncogenic stress to cellular senescence. Cell Cycle 6 August 1 (15) (2007) 1831-1836
14. Bartkova J., Rezaei N., Liontos M., Karakaidos P., Kletsas D., Issaeva N., et al. Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints. Nature 444 November 30 (7119) (2006) 633-637
15. Xue W., Zender L., Miething C., Dickins R.A., Hernando E., Krizhanovsky V., et al. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 445 February 8 (7128) (2007) 656-660
16. Martins C.P., Brown-Swigart L., and Evan G.I. Modeling the therapeutic efficacy of p53 restoration in tumors. Cell 127 December 29 (7) (2006) 1323-1334
17. Ventura A., Kirsch D.G., McLaughlin M.E., Tuveson D.A., Grimm J., Lintault L., et al. Restoration of p53 function leads to tumour regression in vivo. Nature 445 February 8 (7128) (2007) 661-665
18. Patel S., and Player M.R. Small-molecule inhibitors of the p53-HDM2 interaction for the treatment of cancer. Expert Opin Investig Drugs 17 12 (2008) 1865-1882
19. Vassilev L.T. MDM2 inhibitors for cancer therapy. Trends Mol Med 13 1 (2007) 23-31
20. Nambiar P.R., Giardina C., Guda K., Aizu W., Raja R., and Rosenberg D.W. Role of the alternating reading frame (P19)-p53 pathway in an in vivo murine colon tumor model. Cancer Res 62 July 1 (13) (2002) 3667-3674
21. Walchle C., Diwan B.A., Shiao Y.H., and Calvert R.J. Microsatellite instability is infrequent in azoxymethane-induced rat intestinal tumors: an assessment by capillary electrophoresis. Toxicol Appl Pharmacol 157 May 15 (1) (1999) 9-15
22. Erdman S.H., Wu H.D., Hixson L.J., Ahnen D.J., and Gerner E.W. Assessment of mutations in Ki-ras and p53 in colon cancers from azoxymethane- and dimethylhydrazine-treated rats. Mol Carcinog 19 2 (1997) 137-144
23. Shivapurkar N., Belinsky S.A., Wolf D.C., Tang Z., and Alabaster O. Absence of p53 gene mutations in rat colon carcinomas induced by azoxymethane. Cancer Lett 96 September 4 (1) (1995) 63-70
24. Guda K., Upender M.B., Belinsky G., Flynn C., Nakanishi M., Marino J.N., et al. Carcinogen-induced colon tumors in mice are chromosomally stable and are characterized by low-level microsatellite instability. Oncogene 23 May 6 (21) (2004) 3813-3821
25. Aizu W., Belinsky G.S., Flynn C., Noonan E.J., Boes C.C., Godman C.A., et al. Circumvention and reactivation of the p53 oncogene checkpoint in mouse colon tumors. Biochem Pharmacol 72 October 16 (8) (2006) 981-991
26. Thompson T., Tovar C., Yang H., Carvajal D., Vu B.T., Xu Q., et al. Phosphorylation of p53 on key serines is dispensable for transcriptional activation and apoptosis. J Biol Chem 279 December 17 (51) (2004) 53015-53022
27. Belinsky G.S., Claffey K.P., Nambiar P.R., Guda K., and Rosenberg D.W. Vascular endothelial growth factor and enhanced angiogenesis do not promote metastatic conversion of a newly established azoxymethane-induced colon cancer cell line. Mol Carcinog 43 2 (2005) 65-74
28. Burma S., Chen B.P., Murphy M., Kurimasa A., and Chen D.J. ATM phosphorylates histone H2AX in response to DNA double-strand breaks. J Biol Chem 276 November 9 (45) (2001) 42462-42467
29. Vassilev L.T., Vu B.T., Graves B., Carvajal D., Podlaski F., Filipovic Z., et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303 February 6 (5659) (2004) 844-848
30. Tewey K.M., Rowe T.C., Yang L., Halligan B.D., and Liu L.F. Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II. Science 226 October 26 (4673) (1984) 466-468
31. Rowe T., Kupfer G., and Ross W. Inhibition of epipodophyllotoxin cytotoxicity by interference with topoisomerase-mediated DNA cleavage. Biochem Pharmacol 34 July 15 (14) (1985) 2483-2487
32. Long B.H., Musial S.T., and Brattain M.G. Single- and double-strand DNA breakage and repair in human lung adenocarcinoma cells exposed to etoposide and teniposide. Cancer Res 45 7 (1985) 3106-3112
33. Ross W., Rowe T., Glisson B., Yalowich J., and Liu L. Role of topoisomerase II in mediating epipodophyllotoxin-induced DNA cleavage. Cancer Res 44 12 Pt 1 (1984) 5857-5860
34. Sartorelli A.C., and Creasey W.A. The antineoplastic and biochemical effects of some 5-fluoropyrimidines. Cancer Res 27 11 (1967) 2201-2206
35. Goldberg A.R., Machledt Jr. J.H., and Pardee A.B. On the action of fluorouracil on leukemia cells. Cancer Res 26 8 (1966) 1611-1615
36. Bertrand P., Saintigny Y., and Lopez B.S. p53's double life: transactivation-independent repression of homologous recombination. Trends Genet 20 6 (2004) 235-243
37. Gatz S.A., and Wiesmuller L. p53 in recombination and repair. Cell Death Differ 13 6 (2006) 1003-1016
38. Akyuz N., Boehden G.S., Susse S., Rimek A., Preuss U., Scheidtmann K.H., et al. DNA substrate dependence of p53-mediated regulation of double-strand break repair. Mol Cell Biol 22 17 (2002) 6306-6317
39. Saintigny Y., Rouillard D., Chaput B., Soussi T., and Lopez B.S. Mutant p53 proteins stimulate spontaneous and radiation-induced intrachromosomal homologous recombination independently of the alteration of the transactivation activity and of the G1 checkpoint. Oncogene 18 June 17 (24) (1999) 3553-3563
40. Dudenhoffer C., Rohaly G., Will K., Deppert W., and Wiesmuller L. Specific mismatch recognition in heteroduplex intermediates by p53 suggests a role in fidelity control of homologous recombination. Mol Cell Biol 18 9 (1998) 5332-5342
41. Petrini J.H. DNA replication reaches the breaking point. Cell 137 April 17 (2) (2009) 211-212
42. Lopes M., Cotta-Ramusino C., Pellicioli A., Liberi G., Plevani P., Muzi-Falconi M., et al. The DNA replication checkpoint response stabilizes stalled replication forks. Nature 412 August 2 (6846) (2001) 557-561
43. Kitagawa M., Aonuma M., Lee S.H., Fukutake S., and McCormick F. E2F-1 transcriptional activity is a critical determinant of Mdm2 antagonist-induced apoptosis in human tumor cell lines. Oncogene 27 September 11 (40) (2008) 5303-5314
44. Jackson M.W., and Berberich S.J. Constitutive mdmx expression during cell growth, differentiation, and DNA damage. DNA Cell Biol 18 9 (1999) 693-700
45. Bottger V., Bottger A., Garcia-Echeverria C., Ramos Y.F., van der Eb A.J., Jochemsen A.G., et al. Comparative study of the p53-mdm2 and p53-MDMX interfaces. Oncogene 18 January 7 (1) (1999) 189-199
46. Hu B., Gilkes D.M., Farooqi B., Sebti S.M., and Chen J. MDMX overexpression prevents p53 activation by the MDM2 inhibitor Nutlin. J Biol Chem 281 November 3 (44) (2006) 33030-33035
47. Yamaguchi H., Woods N.T., Piluso L.G., Lee H.H., Chen J., Bhalla K.N., et al. p53 acetylation is crucial for its transcription-independent proapoptotic functions. J Biol Chem 284 April 24 (17) (2009) 11171-11183
48. Donner A.J., Hoover J.M., Szostek S.A., and Espinosa J.M. Stimulus-specific transcriptional regulation within the p53 network. Cell Cycle 6 November 1 (21) (2007) 2594-2598
49. Lavin M.F., and Gueven N. The complexity of p53 stabilization and activation. Cell Death Differ 13 6 (2006) 941-950
50. Mallette F.A., Gaumont-Leclerc M.F., and Ferbeyre G. The DNA damage signaling pathway is a critical mediator of oncogene-induced senescence. Genes Dev 21 January 1 (1) (2007) 43-48
51. Bothner B., Lewis W.S., DiGiammarino E.L., Weber J.D., Bothner S.J., and Kriwacki R.W. Defining the molecular basis of Arf and Hdm2 interactions. J Mol Biol 314 November 23 (2) (2001) 263-277
52. Ferbeyre G., de Stanchina E., Lin A.W., Querido E., McCurrach M.E., Hannon G.J., et al. Oncogenic ras and p53 cooperate to induce cellular senescence. Mol Cell Biol 22 10 (2002) 3497-3508
53. Kamijo T., Weber J.D., Zambetti G., Zindy F., Roussel M.F., and Sherr C.J. Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2. Proc Natl Acad Sci USA 95 July 7 (14) (1998) 8292-8297
54. Bartkova J., Horejsi Z., Koed K., Kramer A., Tort F., Zieger K., et al. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 434 April 14 (7035) (2005) 864-870
55. Bouska A., Lushnikova T., Plaza S., and Eischen C.M. Mdm2 promotes genetic instability and transformation independent of p53. Mol Cell Biol 28 15 (2008) 4862-4874
56. Bouska A., and Eischen C.M. Murine double minute 2: p53-independent roads lead to genome instability or death. Trends Biochem Sci 34 6 (2009) 279-286
57. Legube G., Linares L.K., Tyteca S., Caron C., Scheffner M., Chevillard-Briet M., et al. Role of the histone acetyl transferase Tip60 in the p53 pathway. J Biol Chem 279 October 22 (43) (2004) 44825-44833
58. Legube G., Linares L.K., Lemercier C., Scheffner M., Khochbin S., and Trouche D. Tip60 is targeted to proteasome-mediated degradation by Mdm2 and accumulates after UV irradiation. EMBO J 21 April 2 (7) (2002) 1704-1712
59. Eymin B., Claverie P., Salon C., Leduc C., Col E., Brambilla E., et al. p14ARF activates a Tip60-dependent and p53-independent ATM/ATR/CHK pathway in response to genotoxic stress. Mol Cell Biol 26 11 (2006) 4339-4350